Related Experiment Video
Updated: Jul 17, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Brain atrophy in multiple sclerosis: what we know and would like to know
1Department of Radiology, University of Colorado Health Sciences Center, Campus Box A034, Denver, CO 80262, USA. jack.simon@uchsc.edu
Multiple Sclerosis (Houndmills, Basingstoke, England)
|February 1, 2007
Summary
Understanding brain and spinal cord atrophy in multiple sclerosis (MS) is crucial. Current measures face limitations due to complex injury mechanisms and varied pathology expression, impacting treatment effectiveness insights.
Area of Science:
- Neurology
- Neuroscience
- Clinical Trials
Background:
- Brain and spinal cord atrophy measurements are increasingly standard in multiple sclerosis (MS) clinical trials.
- However, the underlying mechanisms driving atrophy and factors influencing variable rates remain poorly understood.
- The impact of treatments on atrophy progression is also unclear.
Purpose of the Study:
- To explore the mechanisms behind brain and spinal cord atrophy in MS.
- To identify factors contributing to variable atrophy rates among individuals and MS phenotypes.
- To understand why treatments may or may not affect atrophy progression.
Main Methods:
- Analysis of existing data from multiple sclerosis clinical trials.
- Review of pathological and imaging studies related to central nervous system (CNS) atrophy.
- Investigating the relationship between injury initiation, temporal factors, and atrophy expression.
Main Results:
- Limitations in current atrophy measures may stem from complex, delayed-expression injury mechanisms.
- Differential effects of focal versus diffuse MS pathology contribute to measurement variability.
- Variable expression of atrophy-related pathology across different CNS tissue locations impacts interpretation.
Conclusions:
- Further research is needed to elucidate the complex mechanisms driving MS-related atrophy.
- Addressing the limitations of atrophy measures requires understanding temporal and spatial pathological factors.
- Improved understanding will enhance the utility of atrophy measures in clinical trials and treatment evaluation.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...